> - "only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission" Not sure why you picked CLL, which is but

> - "only about 25-35% of CAR-T cell recipients with chronic lymphocytic leukaemia experienced a complete remission" Not sure why you picked CLL, which is but one of several diseases that CAR-Ts have been tested against, and which is so far unapproved. Response rates do vary, but are higher than you quote in B-ALL and DLBCL (the diseases that CAR-Ts were first approved for) 83% in B-ALL: https://www.nature.com/articles/nrd.2017.196 https://www.nature.com/articles/nrd.2017.196 82% in ref DLBCL: https://www.nejm.org/doi/full/10.1056/nejmoa1707447 https://www.nejm.org/doi/full/10.1056/nejmoa1707447 64% in DLBCL, 71% in FL: https://www.nejm.org/doi/full/10.1056/NEJMoa1708566 https://www.nejm.org/doi/full/10.1056/NEJMoa1708566